Charnwood Molecular has recently been awarded the Crédit d’Impôt Recherche (CIR) approval from the French Ministère de l’Éducation nationale, de l’Enseignement supérieur et de la Recherche.

CIR logo

A key benefit of this accreditation is to allow our French clients to benefit from significant tax relief on drug discovery research undertaken in partnership with Charnwood Molecular from 2017 through 2019.

For more information on how Charnwood Molecular can bring its “Excellence in Chemistry” to your research projects, please visit:, or contact our Director of Business Development, Dr. Robin Wilkes (

More information on the accreditation can be found here:


Charnwood Molecular was recently featured in an extensive article in the Nottingham Post.

The news article outlines our plans for expansion in 2017, alongside a profile piece on new Head of Medicinal Chemistry, Dr James Hitchin and an insight on the business’ plans from Business Development Director, Dr Robin Wilkes (both pictured above at the BioCity lab).

The full article can be read here:

Charnwood Molecular expansion – Article in Nottingham Post


We have appointed Dr James Hitchin as the new Head of Medicinal Chemistry to lead our research services laboratories at BioCity, Nottingham.

Dr Hitchin brings extensive experience from across multiple therapeutic areas in drug discovery to the Charnwood team. James has previously held positions at SAFC Pharma, Pfizer Pharmaceuticals and KemFine Oy. Most recently he was Senior Medicinal Chemist at the Cancer Research UK Manchester Institute, where he worked on various target classes, including kinases and epigenetic targets from hit identification right through to lead optimization and beyond.

“I am looking forward to the challenge of leading Charnwood Molecular’s Medicinal Chemistry division”, states James. “We are experiencing significant growth in our chemistry services business, including an increase in demand for the medicinal chemistry research that we undertake at the BioCity laboratories. Charnwood’s success is based upon providing extremely high quality, yet cost-effective, solutions for medicinal chemistry projects, becoming the partner of choice for an increasingly diverse client base.”

The appointment will further strengthen Charnwood Molecular’s reputation for excellence in synthesis and customer service, as well as expanding our strength in medicinal chemistry.

James joins a team with existing expertise in a wide range of therapeutic areas, including oncology, obesity, immunology, respiratory disease, inflammation and the treatment of cardiovascular diseases.

James has an impressive publication record covering areas as diverse as the discovery and optimisation of novel allosteric inhibitors of IDH1, the discovery of a highly potent series of TLR7 agonists, and the development and evaluation of selective, reversible LSD1 inhibitors. James’ publication work continues, with a further four papers expected in the short term in high impact journals. He has also been named as an inventor of three patents this year describing the development of inhibitory compounds for both PARG and autotoxin, as well as running a third year medicinal chemistry course for students at the University of Manchester.

Dr Robin Wilkes, Business Development Director of Charnwood Molecular commented: “We are thrilled that James has joined the Charnwood team. We aim to improve clients’ medicinal chemistry initiatives through creativity and innovation and James’ appointment will undoubtedly help in this regard. His appointment is an important advancement towards our plans for future growth, further enhancing the experience of our talented medicinal chemistry group.”

Charnwood Molecular’s work on early stage chemical development for medicinal chemistry projects recently featured in an extensive Chemistry World article, in an interview with Dr David Lathbury.


The divide between contract medicinal chemistry and chemical development needs to be bridged.

That’s the opinion of Dr David Lathbury, who is working with Charnwood Molecular, on its process research and development services for small to mid-sized pharma and biotechnology clients.

The idea is to combine early stage chemical development research with medicinal chemistry projects. By getting chemical development involved earlier, it means the chemistry is better understood before it’s transferred either to another CRO or an in-house team for larger scale production.

‘That way, you have a much better idea of what you’re handing over, and the other side know what they are getting into”, states Dr Lathbury.

The full Chemistry World article, written by Dr Phillip Broadwith, Business Editor of Chemistry World, can be read here: Chemistry World Article.

We’ve now finalised our event schedule through to the end of the year and we have a number of events on the horizon:

Event: The 20th Anniversary UKASF
Date: 7-8 November 2016
Venue: The Imperial War Museum, Duxford, Cambridge, UK

Event: The Chemistry of Collaboration 2016
Date: 8 November 2016
Venue: Alderley Park, Manchester, UK

Event: Antimocrobial Drug Discovery 2016: Plugging the Antibiotics Gap: A Medicinal Chemist’s Perspective
Date: 16 November 2016
Venue: Alderley Park, Manchester, UK

Event: Highlights in Medicinal Chemistry II
Date: 23 November 2016
Venue: London

Event: Recent Disclosures of Clinical Candidates and SMR Award Lecture
Date: 1 December 2016
Venue: NHLI, London

Event: Late Stage Functionalisation for Synthesis and Medicines
Date: 5 December 2016
Venue: Oxford

Should you wish to meet us at any of these, please email us at:

Operating from state-of-the-art research facilities in Loughborough and BioCity, Nottingham, UK, Charnwood Molecular is a leading Contract Research Organisation, providing medicinal, process and synthetic chemistry services to the global pharmaceutical, biotechnology and chemical industries.

As part of an ongoing expansion to meet the rising demand for our services, we are looking to recruit a number of experienced synthetic and medicinal chemists to join our project teams.

Candidate specification:

Ideally PhD qualified with previous experience of working in the following areas within the biotech or pharmaceutical industry:

• Drug Discovery
• Lead Optimisation
• Process Research and Development

Consideration will also be given to experienced graduate level chemists who have worked within these target industries.
We can offer a competitive salary and benefits, including a company pension scheme.

At Charnwood Molecular we recognise that a company’s real strengths lie in the people that it employs. Our strategy is therefore to employ the most talented chemists to bring a wealth of creative experience to the team, and we look forward to receiving your application.

Call to action:

To be considered for these positions please submit a detailed CV and covering letter to:


We are in the process of putting together our conference and exhibition schedule to the end of this year. So far we have a number of events on the horizon:

Event: The Chemistry of Collaboration 2016
Date: 6 October 2016
Venue: Oxford, UK

Event: ELRIG Drug Discovery 2016
Date: 13-14 October 2016
Venue: Liverpool, UK

Event: LATi 2016 Showcase: From Earth to Space and Beyond
Date: 24 October 2016
Venue: Loughborough University Science and Enterprise Park

Event: The 20th Anniversary UKASF
Date: 7-8 November 2016
Venue: The Imperial War Museum, Duxford, Cambridge, UK

Event: Antimocrobial Drug Discovery 2016: Plugging the Antibiotics Gap: A Medicinal Chemist’s Perspective
Date: 16 November 2016
Venue: Alderley Park, Manchester, UK

Should you wish to meet us at any of these events, please email us at:

As you may know, certainly if you were there, we held a draw on our stand across the three main days of EFMC in Manchester last week to win a range of Charnwood beers.

Charnwood Molecular - François-René Alexandre with his prize.

The winners of the specially selected “Charnwood Brewery” box sets are:

• François-René Alexandre of Idenix, France
• Francis Wilson of Summit, UK
• Hans-Peter Buchstaller of Merck, Germany

Pictured – François-René Alexandre with his prize on the Charnwood Molecular EFMC stand.

We look forward to seeing you at the next event/conference.

Mastering Medicinal Chemistry - Boston

We are in attendance at next month’s Mastering Medicinal Chemistry conference, which takes place this year in Boston, MA, USA.

Charnwood Molecular’s, Business Development Director, Dr Robin Wilkes, will be at the event and should you wish to organise in advance to meet up with him, please email him directly at:

The Mastering Medicinal Chemistry conference is now in its 14th year and remains a well-established and popular annual event for senior-level medicinal chemists. The 2016 program features the hottest topics in medicinal chemistry from leaders in the pharmaceutical, biotech and academic spaces. Through cutting-edge case studies, panel discussions, poster presentations and breakout discussions, we showcase the biggest opportunities for small molecules. Several topics will be given special coverage, including small molecules in immuno-oncology, covalent inhibitors, receptor kinetics, CNS kinases, macrocycles, screening diversity, high-throughput experimentation, and novel targets such as RNA, and transporters.

Charnwood at EFMC 2016

We are exhibiting at the forthcoming XXIV EFMC International Symposium on Medicinal Chemistry.

Charnwood Molecular will be exhibiting on Stand 38 in the main exhibition area.

The event is held from 28th August to 1st September 2016 at the International Conference Centre, Manchester, UK.

EFMC is organised by the Biological and Medicinal Chemistry Sector (BMCS) of the Royal Society of Chemistry, on behalf of the European Federation for Medicinal Chemistry (EFMC).

More details on the event can be found here:

If you would like to visit us at the event, please email us at: